Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue: 2021-2025

Historic Cost of Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $20.3 million.

  • Kiniksa Pharmaceuticals International's Cost of Revenue rose 0.74% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year increase of 41.88%. This contributed to the annual value of $60.9 million for FY2024, which is 82.33% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Cost of Revenue of $20.3 million as of Q3 2025, which was up 8.89% from $18.6 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Cost of Revenue high stood at $20.3 million for Q3 2025, and its period low was $491,000 during Q1 2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Cost of Revenue value was $12.3 million (recorded in 2024), while the average stood at $13.1 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue plummeted by 88.36% in 2023 and then soared by 2,055.40% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue (Quarterly) stood at $3.9 million in 2021, then soared by 73.52% to $6.7 million in 2022, then spiked by 42.83% to $9.6 million in 2023, then skyrocketed by 86.73% to $17.9 million in 2024, then climbed by 0.74% to $20.3 million in 2025.
  • Its last three reported values are $20.3 million in Q3 2025, $18.6 million for Q2 2025, and $17.9 million during Q1 2025.